McGill LS, Clay OJ, Edwards KA, Jones KF, Long DM, Johnson MO, Bair MJ, Browne LE, Liebschutz JM, Demonte W, Agil D, Burkholder G, Durr AL, Farel CE, Johnson B, Orris SM, Napravnik S, Thomas T, Merlin JS. Trajectories of Pain Impact and Pain Self-Efficacy in People With HIV and Chronic Pain: Extending Findings From the Skills TO Manage Pain Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2025 Dec 01; 100(4):347-354.

Hawkins KL, Dandachi D, Verzani Z, Brannock MD, Lewis C, Abedian S, Jaferian S, Wuller S, Truong J, Witvliet MG, Dymond G, Mehta HB, Patel PB, Hill E, Weiner MG, Carton TW, Kaushal R, Feuerriegel E, Tran HG, Marks K, Oliveira CR, Gardner EM, Ofotokun I, Gulick RM, Erlandson KM. HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record-Based Cohort Study. Clin Infect Dis. 2025 Oct 06; 81(3):427-438.

Engel N, Sykes C, Schauer AP, Kashuba ADM, Anderson PL, Bushman LR, Cottrell ML. Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application. J Antimicrob Chemother. 2025 Oct 03; 80(10):2727-2731.

Anderson PL, Coppinger C, Cottrell ML, Marzinke MA. Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):162-169.

Edwards KA, Long D, Jones KF, Durr AL, Farel CE, Liebschutz JM, Bair MJ, Agil D, Napravnik S, Browne L, Johnson B, Thomas T, Burkholder G, Clay OJ, Demonte W, Orris SM, Johnson MO, Merlin J. The Skills to Manage Pain Randomized Trial: Results of Antiretroviral Therapy Adherence, HIV Primary Care Retention, and Virologic Suppression Outcomes. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):180-185.

Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL. Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. PLoS Med. 2025 Sep; 22(9):e1004732.

Westergaard RP, Ballard HK, Gicquelais RE, Firnhaber C, Miller R, Wolman M, Liebert C, Steeley E, Mundt MP, Park LS, Quanbeck A. Health System-Level Implementation of Digital Health Support for People Living With HIV and Substance Use Disorders: Protocol for a Cluster-Randomized, Stepped-Wedge Clinical Trial. JMIR Res Protoc. 2025 Aug 29; 14:e69842.

Wilson MP, Erlandson KM, Moore CM, MaWhinney S. The effects of missing data due to study dropout on longitudinal analysis inference using outcome-dependent sampling. Int J Epidemiol. 2025 Aug 18; 54(5).

Parikh UM, Kudrick LD, Levy L, Bosek E, Chohan BH, Mukui I, Masyuko S, Ndlovu N, Mahaka I, Mugurungi O, Ncube G, Hettema A, Matse SN, Mullick S, Wallis CL, Heaps AL, Penrose KJ, McCormick KD, Wiesner L, Anderson PL, Peterson JM, Celum C, Richardson BA, Castor D, Allen S, Torjesen K, Mellors JW. A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa. J Int AIDS Soc. 2025 Aug; 28(8):e70011.

Kline DM, Padmanabhan P, Brewer SE, Cerdá M, Versen E, Keyes KM, Kushel M, Wilson EC, Wesson P, Hyder A, Boyer A, Al-Tayyib A, Barocas JA. Improving health and housing outcomes through a simulation and economic model: an evidence-based protocol of a group model building approach to develop an agent-based model. Front Public Health. 2025; 13:1623385.